Abstract:
OBJECTIVE To investigate the characteristics of multidrug-resistant organisms (MDROs) infections in the patients of intensive care units (ICUs) so as to provide supportive data for precise prevention and control of infections.
METHODS From Jan. 2016 to Dec. 2023, the case-time incidence of hospital-associated MDROs infections, constituent ratios, infection sites and characteristics of drug resistance were observed and compared among the patients from 5 different ICUs of the First Affiliated Hospital of Suzhou University by means of real-time surveillance system of hospital-associated infection.
RESULTS Among the ICU patients, there were 1322 case-times of hospital-associated infections with MDROs, and the case-time incidence rate was 4.67%, which varied in the ICUs. The patients with lower respiratory tract infections accounted for 66.51%, the patients with bloodstream infections 14.53%, the patients with urinary tract infections 10.78%. The distribution of infection sites, distribution of pathogens and etiological spectrum of infection sites varied according to the ICUs. In general, the percentages of carbapenem-resistant Klebsiella pneumoniae (CRKP) and carbapenem-resistant Acinetobacter baumannii (CRAB) infections were highest, which were 35.63%(471/1322) and 38.28% (506/1322), respectively. The drug resistance rates of the CRKP strains to polymyxin B and ceftazidime-avibactam were low, and the drug resistance rate to tigecycline was 38.44%. The drug resistance rates of the CRAB strains to polymyxin B and tigecycline were 10.00% and 21.64%, respectively. The carbapenem-resistant Pseudomonas aeruginosa (CRPA) strains showed high sensitivity to most of the antibiotics. The drug resistance rates of the methicillin-resistant Staphylococcus aureus (MRSA) strains to tetracycline, levofloxacin, gentamicin, moxifloxacin and ciprofloxacin were high.
CONCLUSION It is necessary for the hospital to reasonably use antibiotics based on the result of surveillance of MDROs in the ICUs and take targeted prevention measures for the infections.